3 Overlooked Stocks Set to Soar in 2026

Axsome Therapeutics secured FDA approval for Auvelity in agitation associated with Alzheimer's disease, with a commercial launch planned for June, while 2025 Auvelity sales rose 74% to $507.1 million and total revenue increased 66% to $638.5 million. NovoCure won FDA approval for Optune Pax in advanced pancreatic cancer, and first-quarter revenue rose 12% to $174 million, though it remains loss-making. MBX Biosciences is still pre-revenue but has $459.1 million in cash and expects a fourth-quarter readout for its monthly obesity candidate, MBX 4291, making the article broadly constructive for the trio despite ongoing losses.

Analysis

The market is still pricing these as three separate binary biotech stories, but the common second-order dynamic is commercialization leverage. For AXSM and NVCR, each incremental approval should compress the gap between clinical optionality and operating cash generation, which matters more than headline EPS because these names rerate on gross-to-net durability and launch velocity, not on near-term GAAP profitability. If the launches stick, the real winners are the distributors, specialty pharmacies, and service providers with exposure to higher prescription volumes and reimbursement workflows rather than the broader biotech complex.

The setup is most asymmetric in AXSM: a behavioral-neurology indication with limited direct competition can extend the product lifecycle and reduce dependence on one core depression franchise. The key risk is not efficacy but payer friction and physician adoption speed; if reimbursement is slow, the stock could give back gains quickly despite clinical validation. NVCR’s hidden catalyst is provider certification growth, which can create a nonlinear install-base effect, but that cuts both ways because utilization disappointments show up quickly in quarterly revenue and can re-open doubts about the platform.

MBX is the cleanest long-duration optionality but also the most path-dependent. The market will likely overfocus on the obesity readout and underweight how much cash runway delays the need for dilution, allowing the company to buy time for multiple shots on goal; that lowers financing risk and supports the floor. The contrarian risk is that obesity investors now demand weekly-to-monthly convenience plus differentiated efficacy, so any ambiguous data may be punished harder than the same data would have been two years ago.

Key Decisions for Investors

• Long AXSM into the first 4-8 weeks of the new launch cycle; favor call spreads over common to express upside while capping downside if payer adoption is slower than expected.
• Keep NVCR as a tactical long only on evidence of continued provider certification and reimbursement traction; use a trailing stop because this name can re-rate down quickly if first post-approval utilization disappoints.
• Treat MBX as a long-dated option on obesity differentiation: buy small common or 2027 calls ahead of the late-stage readout, with size limited due to binary trial risk but attractive cash-backed downside protection.
• Pair trade: long AXSM / short a basket of slower-growth commercial biotech names where launch momentum is already fully reflected, to isolate approval-driven rerating from market beta.
• If you own the group, harvest strength on the event and rotate only after the first reimbursement and prescription data print; that is the real validation window, not the FDA decision itself.